Cannabis Science Reports Obama Administration Issues New Medical Marijuana Policy; One More Step Toward Legalization As The Federal Government Won't Prosecute Medical Marijuana If Compliant With State Law

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (OTCBB:CBIS) an emerging pharmaceutical cannabis company, is very pleased with the latest announcement by the Obama Administration. The Company sees it as definitely one giant step closer to the legalization of Medical Cannabis/Marijuana, as a Government supported legal medical treatment.

The Obama Administration said that it would not interfere with medical marijuana programs that are compliant with the laws of the states in which they operate. Two Justice Department officials described the new policy to The Associated Press, saying prosecutors will be told it is not a good use of their time to arrest people who use or provide medical marijuana in strict compliance with state laws.

Dr. Robert Melamede Ph.D. Cannabis Science President and CEO explained, "Although we have never been vulnerable to federal charges in the way that growers and dispensaries might be, this new announcement means that intrastate research in Colorado, California and other states with medical marijuana laws is now explicitly protected from federal prosecution. Clearly, the Obama Administration is moving in the right direction for Cannabis Science Inc., to succeed in its business model."

Previously, Cannabis Science announced initial product development targets and completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis medicines for FDA clinical trials. The Company has determined it will have more than one product in clinical testing and trials at the same time. This news comes following the identification of two distinct parallel paths in developing pharmaceutical products for FDA approval. The first being the highly publicized H1N1 Swine flu and the deadly H1N5 Avian flu, and the second being a newly formed initiative for Veterans who suffer from Post Traumatic Stress Disorder (PTSD). Together with these initiatives, Cannabis Science is laying a solid foundation for entrance into the FDA and other government regulatory agencies for developing medicines for Influenza, PTSD and other ailments.

Dr. Robert Melamede added, "This latest announcement by the Obama Administration clears the way for CBIS to move aggressively in integrating product development and research with local patient groups on a variety of programs. Working within states that have approved the medical use of marijuana, Cannabis Science will be well-ahead in the drive for products that truly help the patients, independently of when Federal laws finally catch up with the states."

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.